Immunomodulation of Antibody-drug Conjugates (ADCs) Virtual Summit

Program Summary

The SITC Summit on Immunomodulation of Antibody-drug Conjugates will highlight the current understanding of antibody-drug conjugates (ADCs) and their effects on the immune system and the tumor microenvironment. ADC monotherapies, ADC combination therapies, and next generation immunoconjugates for targeted cancer therapy will also be discussed. This open-door virtual educational event will present the current state and future directions of the field and feature participation of invited stakeholders involved in ADC research and development, including clinicians and researchers from academia and industry.

Summit Goals and Objectives

The primary objective of the SITC Summit on Immunomodulation of Antibody-drug Conjugates is to elucidate the mechanistic aspects of antibody-drug conjugate (ADC) monotherapies and combination therapies. Secondary goals include exploring the effects of ADCs on the immune system, tumor microenvironment and anti-tumor immunity, reviewing clinical considerations for ADC-based therapies, discussing the rationale of using immunoconjugates for targeted cancer therapy.

Problem Statement

The research and use of antibody-drug conjugates (ADCs) to treat certain cancers have expanded dramatically in the last two years. 2023 brought the first FDA approval of an ADC combined with immune checkpoint blockade, and recent studies suggest that ADCs may modulate the immune system and enhance the anti-cancer immune response. The immuno-oncology field must explore the clinical and translational research surrounding ADCs and their role in immunomodulation, in order to effectively use and design ADCs and ADC-based therapies to improve patient outcomes.